Literature DB >> 6431260

Increased biliary GSSG efflux from rat livers perfused with thiocarbamide substrates for the flavin-containing monooxygenase.

P A Krieter, D M Ziegler, K E Hill, R F Burk.   

Abstract

Thiourea, phenylthiourea, and methimazole perfused into rat liver stimulated the biliary efflux of GSSG without affecting the excretion of GSH into either the bile or the caval perfusate. The thiocarbamide moiety appears essential, since perfusion with urea, phenylurea, or N-methylimidazole did not stimulate GSSG release. Hydrogen peroxide is also not an obligatory intermediate, since thiocarbamide-induced GSSG efflux was undiminished in livers from selenium-deficient animals. The response was also not affected by N-benzylimidazole, a potent cytochrome P-450 inhibitor, which suggests that this monooxygenase is not involved. However, the results are consistent with a model based on S-oxygenation of thiocarbamides to formamadine sulfenates catalyzed exclusively by the flavin-containing monooxygenase. The resulting sulfenate is reduced by GSH, yielding GSSG and the parent thiocarbamide. Rapid cellular oxidation of GSH by this mechanism leads to biliary efflux of the disulfide.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431260

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver.

Authors:  Trine Celius; Andrea Pansoy; Jason Matthews; Allan B Okey; Marilyn C Henderson; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2010-06-04       Impact factor: 4.219

Review 2.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

3.  The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa.

Authors:  Krishna R Veeramah; Mark G Thomas; Michael E Weale; David Zeitlyn; Ayele Tarekegn; Endashaw Bekele; Nancy R Mendell; Elizabeth A Shephard; Neil Bradman; Ian R Phillips
Journal:  Pharmacogenet Genomics       Date:  2008-10       Impact factor: 2.089

4.  Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Sharon K Krueger; J Fred Stevens; Karen Kedzie; Wenkui K Fang; Todd Heidelbaugh; Phong Nguyen; Ken Chow; Michael Garst; Daniel Gil; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2014-04-12       Impact factor: 4.219

5.  Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Jeffrey T Morré; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-01       Impact factor: 4.219

6.  Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide.

Authors:  Asvi A Francois; Clinton R Nishida; Paul R Ortiz de Montellano; Ian R Phillips; Elizabeth A Shephard
Journal:  Drug Metab Dispos       Date:  2008-10-23       Impact factor: 3.922

7.  Cephalosporin-induced alteration in hepatic glutathione redox state. A potential mechanism for inhibition of hepatic reduction of vitamin K1,2,3-epoxide in the rat.

Authors:  M C Mitchell; A Mallat; J J Lipsky
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.